glp-1 drugs review The New Current Insights, Advantages and Challenges

The introduction of insulin in type 2 diabetes mellitus

Pharmacological management of polycystic ovary syndrome

doi: 10.1016/j.neuropharm.2019.107748

The weekly dosing is more forgiving, the bioavailability ensures consistent medication levels, and the weight loss results are backed by extensive clinical research

doi: 10.3389/fendo.2019.00389 Received 07 April 2019 Accepted 30 May 2019 Published 19 June 2019 Volume 10 - 2019 Edited by Jens Juul Holst, University of Copenhagen, Denmark Reviewed by Leon Bach, Monash University, Australia

One article found an increased incidence of aspiration pneumonia among GLP-1 users compared to non-users reporting a hazard ratio of 1.33 (95%CI 1.021.74, p = 0.036) (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)